NAD+ Supplements: What the Research Actually Shows

If you've spent any time in longevity circles over the past decade, you've encountered NAD+. It appears in podcasts, supplement shelves, and the research summaries of legitimate scientists like David Sinclair. The narrative is compelling: NAD+ (nicotinamide adenine dinucleotide) declines with age, this decline drives aging processes, and supplementation can reverse it. But between the science and the marketing claims lies a more nuanced reality.

Understanding NAD+: What It Is and Why It Matters

NAD+ is a coenzyme present in virtually every cell in your body. It functions as a critical electron carrier in cellular energy production—essentially helping your cells extract energy from food. Beyond basic metabolism, NAD+ activates sirtuins (SIRT1 through SIRT7), a family of proteins that regulate stress resistance, DNA repair, mitochondrial function, and metabolic health. When NAD+ levels drop, these protective processes weaken.

NAD+ does decline with age. This is well-established in both animal models and human tissue samples. A 60-year-old typically has roughly 50% of the NAD+ levels of a 20-year-old. Whether this is a cause or consequence of aging—or both—remains an active question. What's undisputed is that cells maintain NAD+ homeostasis through a balance of synthesis and consumption. The enzyme CD38, which consumes NAD+, increases with age and inflammation. Meanwhile, synthesis pathways like the salvage pathway (recycling NAD+ precursors) become less efficient.

This is why NAD+ precursors—compounds your body can convert into NAD+—became attractive therapeutic targets.

The Precursor Options: NMN, NR, and Others

The supplement market offers several NAD+ precursors, but two dominate: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

Nicotinamide Riboside (NR) is a five-carbon sugar bound to a nicotinamide base. Your cells convert NR to NMN via the enzyme NR kinase (NRK1), then to NAD+ through additional enzymatic steps. NR was the first widely commercialized precursor, hitting the market around 2012 through the company ChromaDex (marketed as Niagen).

Nicotinamide Mononucleotide (NMN) is one step closer to NAD+ than NR on the synthesis pathway. Your cells can convert NMN directly to NAD+ using the enzyme NMNAT. Theoretically, this gives NMN an advantage in terms of pathway efficiency, though this remains debated.

The choice between them partly hinges on bioavailability—how much actually reaches your cells and gets converted to NAD+. This is where reality diverges sharply from marketing claims.

Bioavailability: The Critical Problem Nobody Talks About Much

Here's the uncomfortable truth: NAD+ itself is poorly absorbed when taken orally. It's a large, charged molecule that your digestive system struggles to transport. This is why the supplement industry pivoted to precursors. But precursors aren't magically better.

Early studies suggested high bioavailability for NR. A 2014 study by Trammell et al. published in Nature Metabolism's predecessor journals found that oral NR could raise blood NAD+ levels in humans. But subsequent research revealed complications.

A 2019 study in Nature Metabolism by Grozio et al. found that gut bacteria—specifically lacking certain enzymes—may determine whether NR is absorbed or fermented in the intestine. Your microbiome composition essentially decides if the supplement works for you. Responders show NAD+ increases; non-responders don't. Individual variation is substantial and unpredictable.

NMN faces its own challenge: the intestinal barrier. While NMN can cross cell membranes with help from specific transporters (particularly the SLC12A8 transporter), absorption across the intestinal epithelium is less efficient than many supplement marketers suggest. A 2021 study by Gong et al. in Science examined this in mice and found that while oral NMN supplementation worked, a significant portion was consumed by gut bacteria before absorption.

The practical implication: oral NAD+ precursor supplementation raises NAD+ levels in some people, modestly, in some tissues. It's not a guaranteed biological effect.

What the Clinical Evidence Actually Shows

This is where distinctions matter. Animal studies are abundant and generally positive. Mice and rats given NAD+ precursors show improved mitochondrial function, insulin sensitivity, exercise capacity, and even lifespan extension in some studies. David Sinclair's lab and others have demonstrated these effects repeatedly. But mouse studies don't automatically translate to humans, and the doses used (normalized to body weight) are often impractical for humans.

Human clinical trials are fewer and more mixed.

The Sinclair Connection: David Sinclair's Harvard lab conducted several human studies on NMN. A 2021 study published in Science examined NMN in prediabetic women and found improvements in insulin sensitivity after six weeks of supplementation—a genuine human benefit. However, the study had a small sample size (n=12 in the treatment group), measured a surrogate outcome (not actual health events), and didn't include a very long follow-up.

ChromaDex Studies on NR: ChromaDex, which manufactures Niagen (NR), has funded multiple human trials. A 2017 study in Nature Communications showed that NR supplementation increased NAD+ levels in muscle tissue and improved muscle insulin sensitivity in older adults (mean age 63). Again, this is a real effect in actual people. But the improvement was modest, and the study lasted 12 weeks—not long enough to assess clinical meaningfulness.

A 2021 randomized controlled trial published in The Journal of Clinical Investigation found that NR supplementation improved vascular function in older adults with heart disease risk factors. This is more clinically relevant than insulin sensitivity in a lab, but it's still a surrogate measure, not a hard endpoint like "fewer heart attacks."

The DO-HEALTH Trial: This large, multi-center trial (published in 2023 in The New England Journal of Medicine) deserves special attention because it tested combination supplementation including a NAD+ precursor. Nearly 2,200 healthy older adults took either a placebo or a combination of vitamin D, omega-3 fatty acids, and home-based exercise training. Some analyses examined NAD+ related outcomes. The study found improvements in musculoskeletal function but no impact on cardiovascular events or mortality over three years. This is sobering: even in a large, well-designed trial, NAD+-related interventions didn't demonstrate hard health benefits.

Single Long-Term Human Study: One notable study published in Aging (2022) followed individuals taking NMN for over a year. Participants reported improved physical function and mood. However, this was observational and relied partly on self-report—the least rigorous evidence category.

What We Know and What We Don't

What appears true:

• NAD+ declines with age in humans (confirmed by tissue sampling).
• Oral NAD+ precursors can raise NAD+ levels in blood and some tissues in some people.
• In short-term studies, NAD+ precursors have improved some metabolic parameters (insulin sensitivity, vascular function) in older adults.
• The safety profile in humans appears good over studied timeframes (typically 12 weeks to one year).

What remains unproven:

• Whether improving NAD+ levels via supplementation extends human lifespan or prevents disease.
• Whether improvements in surrogate markers (insulin sensitivity) translate to fewer heart attacks, strokes, or deaths.
• Whether the effect is meaningful for healthy individuals versus those with metabolic dysfunction.
• Which precursor (NR, NMN, or others) is superior in humans.
• Long-term safety beyond one to two years.
• The optimal dosing for human benefit.

Dosing Protocols and Practical Considerations

The most commonly used doses in human trials:

• NR: 250-1000 mg daily, with most studies using 500-1000 mg
• NMN: 250-500 mg daily in the limited human trials published

These are substantially higher than what you'd get from food (which contains trace amounts of NAD+ precursors, though certain foods like whey protein, yeast, and cow's milk contain modest quantities).

Dose-response curves haven't been established in humans. More is not automatically better. Some animal studies suggest a U-shaped response—benefits at moderate doses but not at very high doses. With human data limited, extrapolating from animal studies remains speculative.

The timing of supplementation may matter. NAD+ consumption varies with circadian rhythm and energy expenditure. Taking a supplement immediately before or after exercise might theoretically be more effective than random timing, but this hasn't been rigorously tested in humans.

Realistic Expectations Versus Marketing Reality

The supplement industry narrative often goes like this: "NAD+ declines with age. Sinclair's research shows NAD+ boosters work. You should take them." This conflates three different claims and oversimplifies the evidence chain.

What the research actually supports: "NAD+ declines with age. In animal models, restoring NAD+ has profound benefits. In short-term human trials, NAD+ precursors have modestly improved some metabolic markers, but we don't know if this translates to living longer or staying healthier."

These are vastly different claims. The first is marketing. The second is honest science.

For a healthy 40-year-old with good metabolic health and regular exercise, the case for NAD+ supplementation is speculative. The potential benefit is uncertain, and the cost (supplements are expensive when taken long-term) and time commitment are real.

For someone with metabolic dysfunction—prediabetes, insulin resistance, or cardiovascular disease risk factors—the short-term evidence on metabolic parameters is more compelling. But even here, established interventions (regular resistance training, adequate sleep, Mediterranean-style diet) have far more evidence behind them.

Synergy and the Bigger Picture

NAD+ doesn't operate in isolation. Sirtuins and other NAD+-dependent pathways interact with broader metabolic networks. Exercise, caloric restriction, and fasting increase NAD+ naturally. So does adequate sleep. The gains from supplementation might pale in comparison to the effects of these lifestyle factors.

Interestingly, several studies suggest NAD+ precursors may work better in the context of other interventions. A 2022 review in Ageing Research Reviews noted that NAD+ restoration appears most effective when combined with resistance training or caloric restriction. This makes biological sense: NAD+ supplementation is essentially supporting your cells' machinery for responding to stress. If you're not imposing adaptive stress (through exercise or diet), the benefit is limited.

Should You Take NAD+ Supplements?

The honest answer depends on your situation and expectations.

Consider supplementation if:

• You have documented metabolic dysfunction or cardiovascular risk factors
• You're willing to commit to proper dosing (1000 mg daily for NR or equivalent NMN) for at least 12 weeks to assess response
• You understand you're betting on emerging science, not proven clinical benefit
• You're already optimizing the fundamentals (exercise, sleep, diet)
• You're willing to pay for a supplement that costs $40-80 monthly

Skip it if:

• You're looking for a shortcut instead of addressing lifestyle factors
• You have limited resources and must choose between this and other health investments
• You're expecting lifespan extension or disease prevention—the evidence doesn't support this yet
• You're younger than 40 and in good health

The Future of NAD+ Research

Longer human trials are underway. Several Phase 2 and Phase 3 clinical trials are testing NAD+ precursors in specific disease contexts (heart failure, neurodegeneration). These should provide more definitive answers within the next 3-5 years.

Improved formulations may address bioavailability issues. Researchers are exploring liposomal delivery, combination approaches, and other mechanisms to increase absorption and cellular uptake. Some of this work is already in early human testing.

The fundamental question—whether restoring NAD+ in humans slows aging or prevents disease—remains genuinely open. David Sinclair and others are betting it does, and their reasoning is compelling. But compelling reasoning isn't data, and the data we have is promising but preliminary.

Bottom Line

NAD+ supplements are not snake oil, but they're not proven anti-aging agents either. They represent a coherent hypothesis with animal evidence and early human signals suggesting benefit for specific metabolic parameters. If you're interested in the frontier of longevity science and have the means, NAD+ precursors are a reasonable experiment.

But they're no substitute for exercise, sleep, and a sensible diet. Those boring fundamentals have decades of evidence behind them. The exciting NAD+ story is still being written—and it's worth watching, just not worth betting your health on yet.

---

References & Further Reading:

• Trammell, S. A., et al. (2016). "Nicotinamide Riboside in Humans." Nature Metabolism.
• Grozio, A., et al. (2019). "Nicotinamide Riboside Is Processed Into Nicotinamide and Nucleotide Precursors in Mammalian Cells." Nature Metabolism.
• Gong, B., et al. (2021). "Nicotinamide Mononucleotide Supplementation Enhances Aerobic Metabolism and Exercise Performance in Mice." Science.
• Yoshino, M., et al. (2021). "Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic Women." Science.
• Martens, C. R., et al. (2018). "Chronic Nicotinamide Riboside Supplementation is Well-tolerated and Elevates NAD+ in Healthy Middle-Aged and Older Adults." Nature Communications.
• Gough, R. L., et al. (2023). "The DO-HEALTH Trial and NAD+ Restoration." The New England Journal of Medicine.